Even some studies indicated that the presence of BrMs was correlated with inferior survival in patients with NSCLC received anti-PD-1/PD-L1 monotherapy [11, 12], suggesting an unmet treatment need for these populations. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.